Department of Otolaryngology-Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, U.S.A.
Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St. Louis, St. Louis, Missouri, U.S.A.
Laryngoscope. 2019 Nov;129(11):2506-2513. doi: 10.1002/lary.27807. Epub 2019 Jan 13.
OBJECTIVES/HYPOTHESIS: Literature examining long-term survival in head and neck squamous cell carcinoma (HNSCC) with human papillomavirus (HPV) status is lacking. We compare 10-year overall survival (OS) rates for cases to population-based controls.
Prospective cohort study.
Cases surviving 5 years postdiagnosis were identified from the Carolina Head and Neck Cancer Study. We examined 10-year survival by site, stage, p16, and treatment using Kaplan-Meier and Cox proportional hazard models. Cases were compared to age-matched, noncancer controls with stratification by p16 and smoking status.
Ten-year OS for HNSCC is less than controls. In 581 cases, OS differed between sites with p16+ oropharynx having the most favorable prognosis (87%), followed by oral cavity (69%), larynx (67%), p16- oropharynx (56%), and hypopharynx (51%). Initial stage, but not treatment, also impacted OS. When compared to controls matched on smoking status, the hazard ratio (HR) for death in p16+ oropharynx cases was 1.5 (95% confidence interval [CI]: 0.7-3.1) for smokers and 2.4 (95% CI: 0.7-8.8) for nonsmokers. Similarly, HR for death in non-HPV-associated HNSCC was 2.2 (95% CI: 1.7-3.0) for smokers and 2.4 (95% CI: 1.4-4.9) for nonsmokers.
OS for HNSCC cases continues to decrease 5 years posttreatment, even after stratification by p16 and smoking status. Site, stage, smoking, and p16 status are significant factors. These data provide important prognostic information for HNSCC.
2 Laryngoscope, 129:2506-2513, 2019.
目的/假设:缺乏关于人乳头瘤病毒(HPV)状态下的头颈部鳞状细胞癌(HNSCC)长期生存的文献研究。我们比较了病例与基于人群的对照的 10 年总生存率(OS)。
前瞻性队列研究。
从卡罗来纳头颈部癌症研究中确定诊断后存活 5 年的病例。我们通过 Kaplan-Meier 和 Cox 比例风险模型检查了部位、分期、p16 和治疗对 10 年生存率的影响。病例与年龄匹配、p16 和吸烟状况分层的非癌症对照进行比较。
HNSCC 的 10 年 OS 低于对照组。在 581 例病例中,p16+口咽部位的 OS 差异最大,预后最好(87%),其次是口腔(69%)、喉(67%)、p16-口咽(56%)和下咽(51%)。初始分期而不是治疗也影响 OS。与按吸烟状况匹配的对照组相比,p16+口咽病例的死亡风险比(HR)在吸烟者中为 1.5(95%置信区间[CI]:0.7-3.1),在不吸烟者中为 2.4(95% CI:0.7-8.8)。同样,非 HPV 相关 HNSCC 的死亡 HR 在吸烟者中为 2.2(95% CI:1.7-3.0),在不吸烟者中为 2.4(95% CI:1.4-4.9)。
即使按 p16 和吸烟状况分层,HNSCC 病例在治疗后 5 年内 OS 仍继续下降。部位、分期、吸烟和 p16 状态是重要的因素。这些数据为 HNSCC 提供了重要的预后信息。
2 级喉镜,129:2506-2513,2019 年。